Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
- PMID: 33106665
- PMCID: PMC8530434
- DOI: 10.1038/s41591-020-1089-8
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
Abstract
Acute myeloid leukemia (AML) is the most common diagnosed leukemia. In older adults, AML confers an adverse outcome1,2. AML originates from a dominant mutation, then acquires collaborative transformative mutations leading to myeloid transformation and clinical/biological heterogeneity. Currently, AML treatment is initiated rapidly, precluding the ability to consider the mutational profile of a patient's leukemia for treatment decisions. Untreated patients with AML ≥ 60 years were prospectively enrolled on the ongoing Beat AML trial (ClinicalTrials.gov NCT03013998 ), which aims to provide cytogenetic and mutational data within 7 days (d) from sample receipt and before treatment selection, followed by treatment assignment to a sub-study based on the dominant clone. A total of 487 patients with suspected AML were enrolled; 395 were eligible. Median age was 72 years (range 60-92 years; 38% ≥75 years); 374 patients (94.7%) had genetic and cytogenetic analysis completed within 7 d and were centrally assigned to a Beat AML sub-study; 224 (56.7%) were enrolled on a Beat AML sub-study. The remaining 171 patients elected standard of care (SOC) (103), investigational therapy (28) or palliative care (40); 9 died before treatment assignment. Demographic, laboratory and molecular characteristics were not significantly different between patients on the Beat AML sub-studies and those receiving SOC (induction with cytarabine + daunorubicin (7 + 3 or equivalent) or hypomethylation agent). Thirty-day mortality was less frequent and overall survival was significantly longer for patients enrolled on the Beat AML sub-studies versus those who elected SOC. A precision medicine therapy strategy in AML is feasible within 7 d, allowing patients and physicians to rapidly incorporate genomic data into treatment decisions without increasing early death or adversely impacting overall survival.
Figures
Similar articles
-
High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk.Clin Lymphoma Myeloma Leuk. 2012 Dec;12(6):438-43. doi: 10.1016/j.clml.2012.05.007. Epub 2012 Sep 25. Clin Lymphoma Myeloma Leuk. 2012. PMID: 23017331
-
High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.J Clin Oncol. 2014 Jan 20;32(3):219-28. doi: 10.1200/JCO.2013.51.8571. Epub 2013 Dec 2. J Clin Oncol. 2014. PMID: 24297940 Clinical Trial.
-
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients.Ann Oncol. 2018 Apr 1;29(4):973-978. doi: 10.1093/annonc/mdy030. Ann Oncol. 2018. PMID: 29390048 Clinical Trial.
-
Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes.Ann Pharmacother. 2018 Aug;52(8):792-800. doi: 10.1177/1060028018764923. Epub 2018 Mar 13. Ann Pharmacother. 2018. PMID: 29532662 Review.
-
Cytarabine and daunorubicin for the treatment of acute myeloid leukemia.Expert Opin Pharmacother. 2017 Nov;18(16):1765-1780. doi: 10.1080/14656566.2017.1391216. Epub 2017 Oct 20. Expert Opin Pharmacother. 2017. PMID: 29017371 Review.
Cited by
-
Association of genetic variants and survival in patients with acute myeloid leukemia in rural Appalachia.Cancer Rep (Hoboken). 2023 Mar;6(3):e1746. doi: 10.1002/cnr2.1746. Epub 2022 Nov 16. Cancer Rep (Hoboken). 2023. PMID: 36382570 Free PMC article.
-
The PedAL/EuPAL Project: A Global Initiative to Address the Unmet Medical Needs of Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia.Cancers (Basel). 2023 Dec 22;16(1):78. doi: 10.3390/cancers16010078. Cancers (Basel). 2023. PMID: 38201506 Free PMC article.
-
Perspectives and challenges of small molecule inhibitor therapy for FLT3-mutated acute myeloid leukemia.Ann Hematol. 2024 Jul;103(7):2215-2229. doi: 10.1007/s00277-023-05545-3. Epub 2023 Nov 17. Ann Hematol. 2024. PMID: 37975931 Review.
-
Pharmacogenomic Profiling of Pediatric Acute Myeloid Leukemia to Identify Therapeutic Vulnerabilities and Inform Functional Precision Medicine.Blood Cancer Discov. 2022 Nov 2;3(6):516-535. doi: 10.1158/2643-3230.BCD-22-0011. Blood Cancer Discov. 2022. PMID: 35960210 Free PMC article.
-
Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia.J Hematol Oncol. 2023 Aug 3;16(1):91. doi: 10.1186/s13045-023-01480-y. J Hematol Oncol. 2023. PMID: 37537667 Free PMC article.
References
-
- Karjalainen E & Repasky GA Molecular changes during acute myeloid leukemia (AML) evolution and identification of novel treatment strategies through molecular stratification. Prog. Mol. Biol. Transl. Sci 144, 383–436 (2016). - PubMed
-
- Khwaja A et al. Acute myeloid leukaemia. Nat. Rev. Dis. Primers 2, 16010 (2016). - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical